Sputum cell-free DNA for detection of alterations of multiple driver genes in lung adenocarcinoma

摘要

BACKGROUND: Sputum cell-free DNA (cfDNA) has been confirmed to be a valued surrogate sample for detection of EGFR mutations in patients with lung adenocarcinoma (LAC). Whether it is suitable for detection of mutations of multiple driver genes has not been reported. METHODS: A total of 83 patients with LAC were enrolled and their sputum and paired tumor samples were collected. A next-generation sequencing (NGS)-based 10-gene panel was used to test sputum supernatant-derived cfDNA and paired tumor DNA. The sputum sediments were used for cytological evaluation. RESULTS: The total positive rates of hotspot mutations of the 10 driver genes in sputum cfDNA and matched tissue samples were 65.1 and 77.1, respectively. The overall detection sensitivity of variants in sputum cfDNA was 81.3 (95 confidence interval CI, 69.2, 89.5) and the specificity was 100 (95 CI, 79.1, 100). The sensitivities of testing sputum cfDNA from patients with stage IIIB-IV was 87.0 (95 CI, 74.5, 94.1); the sensitivities of testing sputum cfDNA from patients with malignant sputum was 92.3 (95 CI, 78.0, 98.0); and the sensitivity of testing sputum cfDNA from patients with malignant sputum in stage IIIB-IV were 94.1 (95 CI, 78.9, 99.0). CONCLUSIONS: This study demonstrated that sputum cfDNA were successfully used for the detection of multiple driver genes by NGS. Sputum cfDNA could be a valuable surrogate clinical sample for all-in-one test of mutations to guide target therapies, especially for patients with advanced LAC and malignant sputum.